Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Darryl Whitney

Sports Medicine Shelton, CT Medical Doctor

NPI 1285078139 CMS profile 5101807

2 Trap Falls Rd Ste 404, Shelton, CT 06484

Open in the dashboard

General payments

$44,004

53 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Darryl Whitney of Shelton, CT is reported in the CMS Open Payments database as having received $44,004 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $155 3
2024 General $140 4
2023 General $711 8
2022 General $1,585 10
2021 General $146 2
2020 General $8,750 1
2019 General $32,518 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darryl Whitney
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Darryl Whitney were reported at $155. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Darryl Whitney Sports Medicine median Middle half National median
2019 $32,518 $1,176 $199–$4,249 $163
2020 $8,750 $708 $96–$2,890 $114
2021 $146 $1,213 $152–$3,994 $132
2022 $1,585 $1,230 $159–$3,998 $149
2023 $711 $584 $146–$2,836 $160
2024 $140 $628 $163–$3,168 $164
2025 $155 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $23,241 18 payments
  2. Smith+Nephew, Inc. $17,922 8 payments
  3. Stryker Corporation $2,262 14 payments
  4. Joint Restoration Foundation, Inc. $209 1 payment
  5. Polaris Technology Solutions LLC $130 2 payments
  6. DePuy Synthes Sales Inc. $80 3 payments
  7. Vericel Corporation $57 3 payments
  8. Solventum Corporation $37 1 payment
  9. Ardelyx, Inc. $25 1 payment
  10. Pacira Pharmaceuticals Incorporated $22 1 payment
  11. Other $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $20,000 1 payment
  2. Education $19,454 6 payments
  3. Travel and Lodging $2,753 13 payments
  4. Food and Beverage $1,798 33 payments
Products named General payments · program years 2019–2025
  1. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $1,435 6 payments
  2. MAKO $590 3 payments
  3. INSPACE $172 3 payments
  4. NOVOSTITCH $169 3 payments
  5. REGENETEN Extremities & Limb Restoration $130 1 payment
  6. Meniscal Root Repair System $105 1 payment
  7. Dyonics Platinum $105 1 payment
  8. REGENESORB $105 1 payment
  9. Regeneten Sports Med Shoulder $105 1 payment
  10. MICRORAPTOR Knotless Anchor $105 1 payment
  11. Other $469 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

421

Median for Orthopedic Surgery: 203

Drug cost

$3,375

Median for Orthopedic Surgery: $1,433

Branded share of claims

3.8%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 43 $836
Diclofenac Sodium Generic 27 $417
Methocarbamol Generic 47 $414
Methylprednisolone Generic 66 $386
Tizanidine Hcl Generic 42 $248
Meloxicam Generic 95 $237
Ibuprofen Generic 23 $208
Cyclobenzaprine Hcl Generic 35 $189
Gabapentin Generic 13 $176
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 16 $173

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$36,639

Of which drugs: $464

Medicare patients

127

Average age 74

Services billed

4,328

83 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 70%
Diabetes 31%
Ischemic heart disease 28%
Depression 23%
COPD 20%
Osteoporosis 20%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 41 3,920 $394

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record